An open label SLV308 safety extension to study S308.3.003 in early PD patients.

Trial Profile

An open label SLV308 safety extension to study S308.3.003 in early PD patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Pardoprunox (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Solvay Pharmaceuticals
  • Most Recent Events

    • 27 Apr 2010 Trial sponsor, affiliate changed from Solvay Pharmaceuticals to Abbott labs as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Actual number of patients added to 202 as reported by ClinicalTrials.gov.
    • 05 Dec 2008 Actual completion date reported as November 2008 by Clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top